June 2020

A look at the questions you should be asking during the decision-making process of picking a telehealth vendor.

In the wake of the COVID-19 pandemic, health care providers and patients have had to quickly adapt to new formats of care models to promote safety while retaining care standards.

Andrew Russman, DO, guest editor for NeurologyLive, provides insight on how stroke care has changed during the COVID-19 pandemic.

Biohaven’s verdiperstat has entered a phase 3 trial for the treatment of multiple system atrophy, with a new drug application submission on the agenda for late 2021.

An in-depth look into the expanding landscape of multiple sclerosis treatments that target bruton tyrosine kinase.

In this Peer Exchange, sleep experts provide insight into the latest narcolepsy treatments and areas that require further research.

A whole-patient approach to management, coupled with new, more targeted treatments, may help reduce the incidence of medication overuse headache.

Biomarkers in the cerebrospinal fluid and blood could hold the key to early diagnosis of Alzheimer disease.

New drug classes and formulations may help hold off breakthrough activity as the research community works to optimize levodopa delivery and absorption.

The “time is brain” mantra continues to drive innovation in a specialty that will not settle for mediocrity.